Hypereosinophilic syndromes

Common Name(s)

Hypereosinophilic syndromes, Hypereosinophilic syndrome

Hypereosinophilic syndrome (HES) is a condition in which there is an abnormally high number of a certain type of white blood cell called eosinophils. Eosinophils, like all white blood cells, are involved in the immune system. In HES, the number of eosinophils circulating in the blood remains high for a period of over 6 months with no apparent cause. This elevation in eosinophils can affect many organs, such as the heart, nervous system, bone marrow, spleen, or skin.

Symptoms of HES include cardiomyopathy, skin lesions, difficulty breathing, weakness, and numbness. About half of people with HES will also have anemia, or a low number of red blood cells circulating in the blood. This syndrome mostly affects people between the ages of 20 and 50. HES can be caused by certain gene mutations, although in most cases the cause is unknown.

A doctor may use blood tests, bone marrow tests, and imaging tests to rule out other conditions when diagnosing HES. Treatment usually involves medications, such as steroid hormones, and can rarely require surgery. Talk to your doctor about the most current treatment options and which options may be right for you. Support groups can also be a good source of information and encouragement.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hypereosinophilic syndromes" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hypereosinophilic syndromes" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Hypereosinophilic syndromes" returned 5 free, full-text research articles on human participants. First 3 results:

Cardiovascular dysfunction as a common cause of mortality in hypereosinophilic syndromes.
 

Author(s): Grzegorz Helbig, Marek Hus, Katarzyna Brzeźniakiewicz-Janus, Dariusz Woszczyk, Krzysztof Lewandowski, Sławomira Kyrcz-Krzemień

Journal: Pol. Arch. Med. Wewn.. 2015 ;125(9):692-4.

 

Last Updated: 26 Sep 2015

Go To URL
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
 

Author(s): Florence E Roufosse, Jean-Emmanuel Kahn, Gerald J Gleich, Lawrence B Schwartz, Anish D Singh, Lanny J Rosenwasser, Judah A Denburg, Johannes Ring, Marc E Rothenberg, Javed Sheikh, Ann E Haig, Stephen A Mallett, Deborah N Templeton, Hector G Ortega, Amy D Klion

Journal: J. Allergy Clin. Immunol.. 2013 Feb;131(2):461-7.e1-5.

 

Hypereosinophilic syndromes (HESs) are chronic disorders that require long-term therapy to suppress eosinophilia and clinical manifestations. Corticosteroids are usually effective, yet many patients become corticosteroid refractory or develop corticosteroid toxicity. Mepolizumab, ...

Last Updated: 4 Feb 2013

Go To URL
Lung involvement in hypereosinophilic syndromes.
 

Author(s): Megan M Dulohery, Rajesh R Patel, Frank Schneider, Jay H Ryu

Journal: Respir Med. 2011 Jan;105(1):114-21.

 

Hypereosinophilic syndromes (HES) are a heterogeneous group of conditions that are characterized by tissue-associated eosinophilic inflammation and peripheral eosinophilia. Although clinical and radiologic features associated with most forms of eosinophilic lung diseases are relatively ...

Last Updated: 14 Dec 2010

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Hypereosinophilic syndromes" returned 9 free, full-text review articles on human participants. First 3 results:

How I treat hypereosinophilic syndromes.
 

Author(s): Amy D Klion

Journal: Blood. 2015 Aug;126(9):1069-77.

 

Hypereosinophilic syndromes (HESs) are a group of rare disorders characterized by peripheral blood eosinophilia of 1.5 × 10(9)/L or higher and evidence of end organ manifestations attributable to the eosinophilia and not otherwise explained in the clinical setting. HESs are pleomorphic ...

Last Updated: 28 Aug 2015

Go To URL
Therapeutic approaches to patients with hypereosinophilic syndromes.
 

Author(s): Hans-Uwe Simon, Amy Klion

Journal: Semin. Hematol.. 2012 Apr;49(2):160-70.

 

Hypereosinophilic syndromes (HES) are a heterogeneous group of disorders that range from asymptomatic eosinophilia > 1,500/mL to aggressive disease complicated by life-threatening end organ involvement, including endomyocardial fibrosis and thromboembolism. To complicate matters further, ...

Last Updated: 27 Mar 2012

Go To URL
Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.
 

Author(s): Grzegorz Helbig, Sławomira Kyrcz-Krzemień

Journal: Pol. Arch. Med. Wewn.. ;121(1-2):44-52.

 

The hypereosinophilic syndromes (HES) are rare disorders characterized by sustained, nonreactive hypereosinophilia with eosinophilia-associated organ damage/dysfunction. The most frequent clinical manifestations include skin abnormalities, cardiac failure, and neurological deficits, ...

Last Updated: 24 Feb 2011

Go To URL
 
 
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
 

Status: Recruiting

Condition Summary: Hypereosinophilic Syndrome

 

Last Updated: 24 Apr 2017

Go to URL
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
 

Status: Recruiting

Condition Summary: Hypereosinophilic Syndrome

 

Last Updated: 20 Apr 2017

Go to URL
Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
 

Status: Recruiting

Condition Summary: Hypereosinophilic Syndrome

 

Last Updated: 20 Apr 2017

Go to URL